Actor portrayals.
EFFICACY
Two times longer without advanced melanoma skin
cancer worsening*
Half the patients on Opdualag went 2X longer without advanced melanoma worsening than those on a standard treatment.
In a clinical trial of 714 patients with advanced melanoma, 355 were given Opdualag and 359 were given nivolumab alone, a standard treatment.
2X
LONGER
Opdualag
(nivolumab and relatlimab-rmbw)
10 months
In the primary analysis at 13.2 months, half of the patients on Opdualag went 10.1 months without melanoma growing, spreading, or getting worse.
Standard Treatment
(nivolumab)
5 months
In the primary analysis at 13.2 months, half of the patients on standard treatment went 4.6 months without melanoma growing, spreading, or getting worse.
*At the 13.2-month primary analysis, Opdualag reduced the risk of cancer growing, spreading, or getting worse by 25% compared to nivolumab alone. There was no meaningful difference between the two treatments in the length of time that patients were alive.
This study included both BRAF negative and BRAF positive patients.
Opdualag may not work for everyone. Individual results may vary.
Talk to your healthcare team to find out if Opdualag is right for you.
